about
Key Players in Choline Metabolic Reprograming in Triple-Negative Breast CancerCyclophosphamide synergizes with type I interferons through systemic dendritic cell reactivation and induction of immunogenic tumor apoptosisExogenous HIV-1 Nef upsets the IFN-γ-induced impairment of human intestinal epithelial integrityPhosphatidylcholine-specific phospholipase C activation is required for CCR5-dependent, NF-kB-driven CCL2 secretion elicited in response to HIV-1 gp120 in human primary macrophages.Inhibition of phosphatidylcholine-specific phospholipase C downregulates HER2 overexpression on plasma membrane of breast cancer cells.Interferon-α-conditioned human monocytes combine a Th1-orienting attitude with the induction of autologous Th17 responses: role of IL-23 and IL-12.Nuclear phosphoinositide-specific phospholipase C β1 controls cytoplasmic CCL2 mRNA levels in HIV-1 gp120-stimulated primary human macrophages.Apicidin and docetaxel combination treatment drives CTCFL expression and HMGB1 release acting as potential antitumor immune response inducers in metastatic breast cancer cells.IRF-8 controls melanoma progression by regulating the cross talk between cancer and immune cells within the tumor microenvironment.Phospholipases: at the crossroads of the immune system and the pathogenesis of HIV-1 infection.Macrophages and Phospholipases at the Intersection between Inflammation and the Pathogenesis of HIV-1 Infection.Immune surveillance properties of human NK cell-derived exosomes.Human melanoma cells express FGFR/Src/Rho signaling that entails an adhesion-independent caveolin-1 membrane association.Caveolin-1 tumor-promoting role in human melanomaAlterations of choline phospholipid metabolism in ovarian tumor progression.Endothelin A receptor drives invadopodia function and cell motility through the β-arrestin/PDZ-RhoGEF pathway in ovarian carcinoma.Activation of Phosphatidylcholine-Specific Phospholipase C in Breast and Ovarian Cancer: Impact on MRS-Detected Choline Metabolic Profile and Perspectives for Targeted TherapyPhosphatidylcholine-specific phospholipase C inhibition reduces HER2-overexpression, cell proliferation and in vivo tumor growth in a highly tumorigenic ovarian cancer model.IFN-α enhances cross-presentation in human dendritic cells by modulating antigen survival, endocytic routing, and processing.HIV-1 Nef triggers Vav-mediated signaling pathway leading to functional and morphological differentiation of dendritic cells.β-arrestin-1 is a nuclear transcriptional regulator of endothelin-1-induced β-catenin signaling.Type I IFNs control antigen retention and survival of CD8α(+) dendritic cells after uptake of tumor apoptotic cells leading to cross-priming.Endogenous CCL2 (monocyte chemotactic protein-1) modulates human immunodeficiency virus type-1 replication and affects cytoskeleton organization in human monocyte-derived macrophages.Dendritic cells derived from BCG-infected precursors induce Th2-like immune response.Phosphatidylcholine-specific phospholipase C activation in epithelial ovarian cancer cells.hMENA is a key regulator in endothelin-1/β-arrestin1-induced invadopodial function and metastatic process.NK Cell Activation in the Antitumor Response Induced by IFN-α Dendritic Cells Loaded with Apoptotic Cells from Follicular Lymphoma Patients.A non-conserved amino acid variant regulates differential signalling between human and mouse CD28.LOX-1 as a natural IFN- -mediated signal for apoptotic cell uptake and antigen presentation in dendritic cellsFunctional role of phosphatidylcholine-specific phospholipase C in regulating CD16 membrane expression in natural killer cellsExpression and role of phosphatidylcholine-specific phospholipase C in human NK and T lymphocyte subsetsIL-2 induces expression and secretion of IFN-γ in murine peritoneal macrophagesDifferential expression and distribution of ezrin, radixin and moesin in human natural killer cellsLenalidomide improves the therapeutic effect of an interferon-α-dendritic cell-based lymphoma vaccineIL-33 Promotes CD11b/CD18-Mediated Adhesion of Eosinophils to Cancer Cells and Synapse-Polarized Degranulation Leading to Tumor Cell Killing
P50
Q28074613-E28EDA58-CA78-4372-AC55-2BA32DA0D0CEQ28300987-4884DFE3-7416-42EC-965D-DE326FDAE92DQ28741652-3ECA9E88-0442-4427-95C2-AC756167A2DCQ33315307-0D81E7A0-FBFF-4A41-9721-08B281A4BDC1Q33576337-60F508EA-3082-4086-84C0-21A45EC51B9DQ33840997-4922F198-0DC8-4249-A458-8ED9DBDA1876Q34651978-6A7656A4-CD8B-4EBB-99D4-54F4AAB8E607Q36282754-19BD03D9-4357-49B3-AED3-B48B3C4B2332Q36520732-1210E572-9DB5-4723-B1C1-5326436C214CQ38996186-647D9EF0-48AD-48AC-8189-4FCFB1B644D2Q39404652-67BEAE8F-1A33-43E2-876F-99A0E1E1C21DQ39567116-5FF6882E-38F8-4505-99DC-BFC329F224A0Q39568935-9302DAA8-10E7-47C4-BFE4-5588373B0B49Q39838942-BDA57ADD-72C4-43C4-9281-81DA2E23CB0CQ40360938-DDE3CD07-4030-4669-89F8-5D700EB0AB34Q40368919-EF86DF35-0600-45E7-A43A-D22DB5DE67EDQ40572969-5CD62121-F219-4D68-8478-033AA0C2675EQ41549845-DFA80EC4-AC07-4F84-8148-EF7770F13EDBQ43047480-C81EB686-84FF-4B72-A3B9-FFC8B846E734Q44642079-6B8D662A-62C2-4A3D-9BE6-C60C85E6D16CQ44686499-282A9837-72A5-40C5-9934-9B12FBBE8EDDQ45397464-4F2F2E04-C2EA-40F3-B8D0-0F950952DCE8Q45722952-590EA9B7-3685-4D43-B1C3-8DE3E2130648Q47231079-B15B8BB2-EEA6-4446-A7AD-70327BEDF3BDQ47400582-43C8C93B-C4FC-421B-A84D-4E7F190E1A2CQ50035034-17CFA7BB-4007-4964-8F98-29B593CDB8E1Q51673761-A45F7120-A8D5-4896-ABA7-EC77B286101AQ55174942-7840D894-17A7-4461-94A1-376D8807C1DFQ60658471-95FD234C-4F8B-4C99-B5A5-D543BEF7A5AAQ61738816-02C01628-D2E3-4D75-9A20-A823E2880F05Q61738822-CFA756E3-08F9-4B1E-98C2-5D198B53037AQ61738830-9C14034E-6F1C-40CA-BDD2-655317FC4A50Q78387526-AAD33146-A851-4CE1-AE71-32A99685C2E6Q90761792-0ED5FD47-13FC-4D45-AA2A-5BE8781CDBF5Q91254181-B7C64BCB-42E8-446C-A73A-FD181DCC3D23
P50
description
hulumtuese
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Francesca Spadaro
@ast
Francesca Spadaro
@en
Francesca Spadaro
@es
Francesca Spadaro
@nl
Francesca Spadaro
@sl
type
label
Francesca Spadaro
@ast
Francesca Spadaro
@en
Francesca Spadaro
@es
Francesca Spadaro
@nl
Francesca Spadaro
@sl
prefLabel
Francesca Spadaro
@ast
Francesca Spadaro
@en
Francesca Spadaro
@es
Francesca Spadaro
@nl
Francesca Spadaro
@sl
P1053
M-7512-2017
P106
P21
P31
P3829
P496
0000-0002-6610-350X